First-in-human study starts include radioligands from Akiram and Philogen.

The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.

The French group takes a shot at Perspective with its second bet on Orano Med.

Meanwhile, Tecvayli stalls, but J&J still hopes for growth.

Jazz's somewhat low-key SCLC drug scores its biggest win yet.